LifeMD Reports Third Quarter 2024 Results

GlobeNewswire11-08

Total revenues increased 38% year-over-year to $53.4 million with telehealth revenue up 65% Record gross margin of 90.6%, up 300 basis points from the year-ago period Adjusted EBITDA increased 33% to ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481160767?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Ls.HxuncEKXZVpPdSIIBVA--~B/aD0xMDAwO3c9MzQ1NTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/3fddd422a379304d09af48e0f840b88a","is_english":true,"pubTime":"2024-11-08 05:05","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2481160767","market":"us","top_or_hot":-1,"title":"LifeMD Reports Third Quarter 2024 Results","media":"GlobeNewswire","content":"<div>\n<p>Total revenues increased 38% year-over-year to $53.4 million with telehealth revenue up 65%\nRecord gross margin of 90.6%, up 300 basis points from the year-ago period\nAdjusted EBITDA increased 33% to ...</p>\n\n<a href=\"https://finance.yahoo.com/news/lifemd-reports-third-quarter-2024-210500001.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LifeMD Reports Third Quarter 2024 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLifeMD Reports Third Quarter 2024 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-08 05:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/lifemd-reports-third-quarter-2024-210500001.html><strong>GlobeNewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Total revenues increased 38% year-over-year to $53.4 million with telehealth revenue up 65%\nRecord gross margin of 90.6%, up 300 basis points from the year-ago period\nAdjusted EBITDA increased 33% to ...</p>\n\n<a href=\"https://finance.yahoo.com/news/lifemd-reports-third-quarter-2024-210500001.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4183","symbol_name":"个人用品","start_time":0,"source_url":"https://finance.yahoo.com/news/lifemd-reports-third-quarter-2024-210500001.html","article_id":"2481160767","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Ls.HxuncEKXZVpPdSIIBVA--~B/aD0xMDAwO3c9MzQ1NTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/3fddd422a379304d09af48e0f840b88a"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481160767","pubTimestamp":1731013500,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Total revenues increased 38% year-over-year to $53.4 million with telehealth revenue up 65%. Record gross margin of 90.6%, up 300 basis points from the year-ago period. Telehealth adjusted EBITDA of $2.5 million, a 200% sequential increase versus the second quarter. Generated $6.2 million of cash flow from operations in the third quarter and positive net cash flow in each of the last four quarters. “LifeMD had a strong quarter with top- and bottom-line growth led by our core telehealth business. Not only did this business achieve 65% year-over-year growth on a standalone basis and patient subscriber base grew to approximately 269,000 at quarter-end, but telehealth adjusted EBITDA increased 200% sequentially to $2.5 million. Although WorkSimpli’s financial results continued to be pressured, the business returned to sequential subscriber growth and is still forecasted to reach peak monthly profitability by year-end,” commented Marc Benathen, Chief Financial Officer of LifeMD. “Cash flow ","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4183":"个人用品","BK4167":"医疗保健技术","LFMD":"LifeMD Inc.","LFMDP":"LifeMD Inc."},"translate_title":"LifeMD报告2024年第三季度业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LFMD":0.9,"LFMDP":0.9},"content_text":"Total revenues increased 38% year-over-year to $53.4 million with telehealth revenue up 65%\nRecord gross margin of 90.6%, up 300 basis points from the year-ago period\nAdjusted EBITDA increased 33% to $3.7 million\nTelehealth adjusted EBITDA of $2.5 million, a 200% sequential increase versus the second quarter\nCash of $37.6 million as of September 30, 2024\nGenerated $6.2 million of cash flow from operations in the third quarter and positive net cash flow in each of the last four quarters\n\nConference call begins at 4:30 p.m. Eastern time today\nNEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today reported financial results for the three and nine months ended September 30, 2024.\nManagement Commentary\n“LifeMD’s core telehealth business had another very strong quarter, led by outperformance in both our Rex® MD and virtual primary care verticals. We not only are very pleased with our tremendous growth rate, but also with the exponential increase in sequential profitability of our telehealth business,” said Justin Schreiber, Chairman and CEO of LifeMD. “As we pursue our vision to become the leading provider of direct-to-consumer virtual healthcare services, we continue to make significant investments in our technology platform, affiliated medical group and differentiated products that help patients live healthier and happier lives. In the third quarter, we launched in-home laboratory services, a safe and efficacious non-GLP-1 weight management therapy, and our men’s hormonal therapy offering under our Rex MD brand. We also made progress with our 6S Framework wellness program, including the launch of a 50-state nutrition counseling program. I am particularly excited about the recent opening of our national, vertically integrated pharmacy, which will be accretive in 2025 and enables LifeMD to become a fully integrated, end-to-end provider of virtual healthcare services. These advancements continue to underscore our commitment to virtual healthcare market leadership across a range of categories and capabilities.”\n“LifeMD had a strong quarter with top- and bottom-line growth led by our core telehealth business. Not only did this business achieve 65% year-over-year growth on a standalone basis and patient subscriber base grew to approximately 269,000 at quarter-end, but telehealth adjusted EBITDA increased 200% sequentially to $2.5 million. Although WorkSimpli’s financial results continued to be pressured, the business returned to sequential subscriber growth and is still forecasted to reach peak monthly profitability by year-end,” commented Marc Benathen, Chief Financial Officer of LifeMD. “Cash flow continued to increase and remained exceptionally strong. For the third quarter, LifeMD generated over $6 million of operating cash flow and bolstered its cash balance by approximately $2 million to $37.6 million as of September 30th. Our strong unit economics, consistent cash flow generation and strengthened balance sheet continue to support our ability to optimize our corporate investment needs.”\nThird Quarter Financial HighlightsAll comparisons are with the third quarter of 2023.\n\nTotal revenues increased 38% to $53.4 million with telehealth revenue up 65%.\nTelehealth active subscribers increased 30% to approximately 269,000 at quarter-end.\nWorkSimpli active subscribers decreased 6% to approximately 161,000 at quarter-end but grew sequentially by approximately 2,000 subscribers.\nGross margin expanded to 90.6%, up from 87.6%.\nGAAP net loss was $5.9 million or $0.14 per share, compared with $6.9 million or $0.20 per share.\nAdjusted EBITDA was $3.7 million compared with $2.8 million (see definition below of this non-GAAP financial measure and reconciliation to GAAP).\nThe telehealth business achieved adjusted EBITDA profitability of $2.5 million compared with a loss of $2.3 million (see definition below of this non-GAAP financial measure and reconciliation to GAAP).\nAdjusted diluted EPS was $0.09 compared with $0.08 (see definition below of this non-GAAP financial measure and reconciliation to GAAP).\nCash and cash equivalents were $37.6 million as of September 30, 2024.\n\nThird Quarter Key Performance Metrics\n\n\n\n($ in 000s)\nThree Months Ended Sept 30,\n \nY-o-Y\n\n\nKey Performance Metrics\n2024\n2023\n \n% Growth\n\n\nRevenue\n \n \n \n \n \n \n \n\n\nTelehealth\n$\n40,276\n \n$\n24,343\n \n65%\n\n\nWorkSimpli\n$\n13,118\n \n$\n14,271\n \n-8%\n\n\nTotal Revenue\n$\n53,393\n \n$\n38,614\n \n38%\n\n\n \n \n \n \n \n \n \n \n\n\nActive Subscribers\n \n \n \n \n \n \n \n\n\nTelehealth Active Subscribers\n \n268,739\n \n \n206,536\n \n30%\n\n\nWorkSimpli Active Subscribers\n \n160,864\n \n \n170,388\n \n-6%\n\n\nTotal Active Subscribers\n \n429,603\n \n \n376,924\n \n14%\n\n\n \n \n \n \n \n \n \n \n\n\n\nFinancial Guidance\nFor the fourth quarter of 2024, the Company expects:\n\nTotal revenues in the range of $57 million to $58 million, with telehealth revenue in the range of $43 million to $44 million and WorkSimpli revenue of approximately $14 million.\nAdjusted EBITDA in the range of $6.5 million to $7.0 million, with telehealth adjusted EBITDA in the range of $4.0 million to $4.5 million.\n\nFor the full year 2024, the Company expects:\n\nTotal revenues of at least $205 million, unchanged from previous guidance, with telehealth revenue guidance increased to a range of $151 million to $152 million, from $150 million previously, and WorkSimpli revenue guidance decreased to $54 million, from $55 million previously.\nAdjusted EBITDA narrowed to a range of $13 million to $14 million, from $13 million to $15 million previously, with telehealth adjusted EBITDA guidance increased to a range of $6 million to $7 million, from $3 million to $4 million previously.\n\nConference Call\nLifeMD’s management will host a conference call today at 4:30 p.m. Eastern time to discuss the Company’s financial results and outlook, and answer questions. Details for the call are as follows:\n\n\n\nToll-free dial-in number:\n800-717-1738\n\n\nInternational dial-in number:\n646-307-1865\n\n\nConference ID:\n73461\n\n\n \n \n\n\n\nA live and archived webcast will be available in the Investors section of the Company’s website at ir.lifemd.com.\nAbout LifeMD\nLifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men’s and women's health, weight management, and hormone therapy. The Company leverages a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a 22,500-square-foot affiliated pharmacy, and a U.S.-based patient care center to increase access to high-quality and affordable care. For more information, please visit LifeMD.com.\nCautionary Note Regarding Forward Looking Statements\nThis news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: “believe,” “expect,” “anticipate,” “project,” “should,” “plan,” “will,” “may,” “intend,” “estimate,” predict,” “continue,” and “potential,” or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition.\nForward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, “Risk Factors” identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.\nAny forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.\nInvestor ContactLifeMD, Inc.Marc Benathen, Chief Financial Officermarc@lifemd.com\nMedia ContactJessica Friedeman, Chief Marketing Officerpress@lifemd.com\nTables to Follow\n\n\n\nLIFEMD, INC.\n\n\nCONDENSED CONSOLIDATED BALANCE SHEETS\n\n\n \n \n \n \n \n \n \n \n\n\n \nSeptember 30, 2024\n \nDecember 31, 2023\n\n\n \n(Unaudited)\n \n \n \n \n\n\nASSETS\n\n\n \n \n \n \n \n \n \n \n\n\nCurrent Assets\n \n \n \n \n \n \n \n\n\nCash\n$\n37,587,253\n \n \n$\n33,146,725\n \n\n\nAccounts receivable, net\n \n6,049,501\n \n \n \n5,277,250\n \n\n\nProduct deposit\n \n136,755\n \n \n \n485,850\n \n\n\nInventory, net\n \n2,645,443\n \n \n \n2,759,932\n \n\n\nOther current assets\n \n2,238,005\n \n \n \n934,510\n \n\n\nTotal Current Assets\n \n48,656,957\n \n \n \n42,604,267\n \n\n\n \n \n \n \n \n \n \n \n\n\nNon-current Assets\n \n \n \n \n \n \n \n\n\nEquipment, net\n \n1,420,052\n \n \n \n476,303\n \n\n\nRight of use assets\n \n6,750,256\n \n \n \n594,897\n \n\n\nCapitalized software, net\n \n13,457,432\n \n \n \n11,795,979\n \n\n\nIntangible assets, net\n \n2,275,225\n \n \n \n3,009,263\n \n\n\nTotal Non-current Assets\n \n23,902,965\n \n \n \n15,876,442\n \n\n\n \n \n \n \n \n \n \n \n\n\nTotal Assets\n$\n72,559,922\n \n \n$\n58,480,709\n \n\n\n \n \n \n \n \n \n \n \n\n\nLIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' EQUITY (DEFICIT)\n \n \n \n \n \n \n \n\n\n \n \n \n \n \n \n \n \n\n\nCurrent Liabilities\n \n \n \n \n \n \n \n\n\nAccounts payable\n$\n15,867,469\n \n \n$\n11,084,855\n \n\n\nAccrued expenses\n \n21,013,174\n \n \n \n13,937,494\n \n\n\nNotes payable, net\n \n-\n \n \n \n327,597\n \n\n\nCurrent operating lease liabilities\n \n403,319\n \n \n \n603,180\n \n\n\nCurrent portion of long-term debt\n \n5,277,778\n \n \n \n-\n \n\n\nDeferred revenue\n \n16,390,541\n \n \n \n8,828,598\n \n\n\nTotal Current Liabilities\n \n58,952,281\n \n \n \n34,781,724\n \n\n\n \n \n \n \n \n \n \n \n\n\nLong-term Liabilities\n \n \n \n \n \n \n \n\n\nLong-term debt, net\n \n12,951,280\n \n \n \n17,927,727\n \n\n\nNoncurrent operating lease liabilities\n \n6,511,425\n \n \n \n73,849\n \n\n\nContingent consideration\n \n100,000\n \n \n \n131,250\n \n\n\nTotal Liabilities\n \n78,514,986\n \n \n \n52,914,550\n \n\n\n \n \n \n \n \n \n \n \n\n\nCommitments and Contingencies\n \n \n \n \n \n \n \n\n\nMezzanine Equity\n \n \n \n \n \n \n \n\n\nPreferred Stock, $0.0001 par value; 5,000,000 shares authorized Series B Convertible Preferred Stock, $0.0001 par value; 5,000 shares authorized, zero shares issued and outstanding, liquidation value, $0 per share as of September 30, 2024 and December 31, 2023\n \n-\n \n \n \n-\n \n\n\nStockholders’ Equity (Deficit)\n \n \n \n \n \n \n \n\n\nSeries A Preferred Stock, $0.0001 par value; 1,610,000 shares authorized, 1,400,000 shares issued and outstanding, liquidation value approximately $25.55 per share as of September 30, 2024 and December 31, 2023\n \n140\n \n \n \n140\n \n\n\nCommon Stock, $0.01 par value; 100,000,000 shares authorized, 41,909,572 and 38,358,641 shares issued, 41,806,532 and 38,255,601 outstanding as of September 30, 2024 and December 31, 2023, respectively\n \n419,096\n \n \n \n383,586\n \n\n\nAdditional paid-in capital\n \n227,394,727\n \n \n \n217,550,583\n \n\n\nAccumulated deficit\n \n(235,370,384\n)\n \n \n(214,265,236\n)\n\n\nTreasury stock, 103,040 shares, at cost, as of September 30, 2024 and December 31, 2023\n \n(163,701\n)\n \n \n(163,701\n)\n\n\nTotal LifeMD, Inc. Stockholders’ (Deficit) Equity\n \n(7,720,122\n)\n \n \n3,505,372\n \n\n\nNon-controlling interest\n \n1,765,058\n \n \n \n2,060,787\n \n\n\nTotal Stockholders’ (Deficit) Equity\n \n(5,955,064\n)\n \n \n5,566,159\n \n\n\nTotal Liabilities, Mezzanine Equity and Stockholders’ Equity (Deficit)\n$\n72,559,922\n \n \n$\n58,480,709\n \n\n\n \n \n \n \n \n \n \n \n\n\n\n\n\n\nLIFEMD, INC.  \n\n\nCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS\n\n\n(Unaudited)\n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n \nThree Months Ended September 30,\n \nNine Months Ended September 30,\n\n\n \n2024\n \n2023\n \n2024\n \n2023\n\n\nRevenues\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nTelehealth revenue, net\n$\n          40,275,546\n \n \n$\n          24,342,789\n \n \n$\n        108,549,257\n \n \n$\n          66,896,719\n \n\n\nWorkSimpli revenue, net\n \n          13,117,611\n \n \n \n          14,271,122\n \n \n \n          39,650,009\n \n \n \n          40,790,439\n \n\n\nTotal revenues, net\n \n          53,393,157\n \n \n \n          38,613,911\n \n \n \n        148,199,266\n \n \n \n        107,687,158\n \n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nCost of revenues\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nCost of telehealth revenue\n \n            4,300,877\n \n \n \n            4,479,760\n \n \n \n          13,049,315\n \n \n \n          12,525,887\n \n\n\nCost of WorkSimpli revenue\n \n               712,664\n \n \n \n               301,746\n \n \n \n            1,589,318\n \n \n \n            1,019,018\n \n\n\nTotal cost of revenues\n \n            5,013,541\n \n \n \n            4,781,506\n \n \n \n          14,638,633\n \n \n \n          13,544,905\n \n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nGross profit\n \n          48,379,616\n \n \n \n          33,832,405\n \n \n \n        133,560,633\n \n \n \n          94,142,253\n \n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nExpenses \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nSelling and marketing expenses\n \n          26,611,672\n \n \n \n          19,776,797\n \n \n \n          77,164,480\n \n \n \n          56,062,345\n \n\n\nGeneral and administrative expenses\n \n          18,925,844\n \n \n \n          13,398,387\n \n \n \n          52,752,961\n \n \n \n          36,120,723\n \n\n\nCustomer service expenses\n \n            2,804,210\n \n \n \n            2,106,252\n \n \n \n            7,385,669\n \n \n \n            5,573,734\n \n\n\nOther operating expenses\n \n            2,112,169\n \n \n \n            1,622,137\n \n \n \n            6,318,791\n \n \n \n            4,640,690\n \n\n\nDevelopment costs\n \n            2,611,833\n \n \n \n            1,498,213\n \n \n \n            7,101,655\n \n \n \n            4,062,498\n \n\n\nTotal expenses\n \n          53,065,728\n \n \n \n          38,401,786\n \n \n \n        150,723,556\n \n \n \n        106,459,990\n \n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nOperating loss\n \n          (4,686,112\n)\n \n \n          (4,569,381\n)\n \n \n        (17,162,923\n)\n \n \n        (12,317,737\n)\n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nOther expenses\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nInterest expense, net\n \n             (558,597\n)\n \n \n             (713,766\n)\n \n \n          (1,567,743\n)\n \n \n          (1,973,901\n)\n\n\nLoss on debt extinguishment\n \n                        -  \n \n \n \n                        -  \n \n \n \n                        -  \n \n \n \n             (325,198\n)\n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nNet loss before income taxes\n \n          (5,244,709\n)\n \n \n          (5,283,147\n)\n \n \n        (18,730,666\n)\n \n \n        (14,616,836\n)\n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nIncome tax expense\n \n             (232,523\n)\n \n \n                        -  \n \n \n \n             (232,523\n)\n \n \n                        -  \n \n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nNet loss\n \n          (5,477,232\n)\n \n \n          (5,283,147\n)\n \n \n        (18,963,189\n)\n \n \n        (14,616,836\n)\n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nNet (loss) income attributable to noncontrolling interests\n \n             (345,767\n)\n \n \n               839,288\n \n \n \n             (187,729\n)\n \n \n            2,247,055\n \n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nNet loss attributable to LifeMD, Inc.\n \n          (5,131,465\n)\n \n \n          (6,122,435\n)\n \n \n        (18,775,460\n)\n \n \n        (16,863,891\n)\n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nPreferred stock dividends\n \n             (776,563\n)\n \n \n             (776,563\n)\n \n \n          (2,329,688\n)\n \n \n          (2,329,688\n)\n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nNet loss attributable to LifeMD, Inc. common stockholders\n$\n          (5,908,028\n)\n \n$\n          (6,898,998\n)\n \n$\n        (21,105,148\n)\n \n$\n        (19,193,579\n)\n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nBasic loss per share attributable to LifeMD, Inc. common stockholders\n$\n                   (0.14\n)\n \n$\n                   (0.20\n)\n \n$\n                   (0.52\n)\n \n$\n                   (0.58\n)\n\n\nDiluted loss per share attributable to LifeMD, Inc. common stockholders\n$\n                   (0.14\n)\n \n$\n                   (0.20\n)\n \n$\n                   (0.52\n)\n \n$\n                   (0.58\n)\n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nWeighted average number of common shares outstanding:\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nBasic\n \n          42,020,965\n \n \n \n          34,472,904\n \n \n \n          40,857,344\n \n \n \n          32,959,665\n \n\n\nDiluted\n \n          42,020,965\n \n \n \n          34,472,904\n \n \n \n          40,857,344\n \n \n \n          32,959,665\n \n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n\n\n\n\nLIFEMD, INC.\n\n\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n\n\n(Unaudited)\n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n \nThree Months Ended September 30,\n \nNine Months Ended September 30,\n\n\n \n2024\n \n2023\n \n2024\n \n2023\n\n\n \n \n \n \n \n \n \n \n\n\nCASH FLOWS FROM OPERATING ACTIVITIES\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nNet loss\n$\n(5,477,232\n)\n \n$\n(5,283,147\n)\n \n$\n(18,963,189\n)\n \n$\n(14,616,836\n)\n\n\nAdjustments to reconcile net loss to net cash provided by operating activities:\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nAmortization of debt discount\n \n100,443\n \n \n \n79,653\n \n \n \n301,331\n \n \n \n233,495\n \n\n\nAmortization of capitalized software\n \n2,159,781\n \n \n \n1,439,049\n \n \n \n5,884,893\n \n \n \n3,787,716\n \n\n\nAmortization of intangibles\n \n245,804\n \n \n \n245,968\n \n \n \n737,836\n \n \n \n725,496\n \n\n\nAccretion of consideration payable\n \n-\n \n \n \n34,265\n \n \n \n13,644\n \n \n \n148,481\n \n\n\nDepreciation of fixed assets\n \n151,332\n \n \n \n49,852\n \n \n \n321,698\n \n \n \n146,286\n \n\n\nLoss on debt extinguishment\n \n-\n \n \n \n-\n \n \n \n-\n \n \n \n325,198\n \n\n\nOperating lease payments\n \n137,641\n \n \n \n191,645\n \n \n \n529,038\n \n \n \n562,073\n \n\n\nStock issued for legal settlement\n \n-\n \n \n \n532,000\n \n \n \n-\n \n \n \n532,000\n \n\n\nStock compensation expense\n \n2,394,235\n \n \n \n3,318,253\n \n \n \n9,129,841\n \n \n \n8,843,736\n \n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nChanges in Assets and Liabilities\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nAccounts receivable\n \n(381,559\n)\n \n \n(750,039\n)\n \n \n(772,251\n)\n \n \n(1,583,832\n)\n\n\nProduct deposit\n \n(20,621\n)\n \n \n150,347\n \n \n \n349,095\n \n \n \n42,497\n \n\n\nInventory\n \n(584,724\n)\n \n \n(92,344\n)\n \n \n114,489\n \n \n \n(87,283\n)\n\n\nOther current assets\n \n(716,585\n)\n \n \n(631,765\n)\n \n \n(1,303,495\n)\n \n \n(616,938\n)\n\n\nOperating lease liabilities\n \n(111,892\n)\n \n \n(201,667\n)\n \n \n(446,682\n)\n \n \n(589,744\n)\n\n\nDeferred revenue\n \n1,228,882\n \n \n \n571,144\n \n \n \n7,561,943\n \n \n \n691,848\n \n\n\nAccounts payable\n \n815,740\n \n \n \n44,011\n \n \n \n4,782,614\n \n \n \n(469,403\n)\n\n\nAccrued expenses\n \n6,261,674\n \n \n \n1,378,992\n \n \n \n7,704,036\n \n \n \n5,611,131\n \n\n\nOther operating activity\n \n-\n \n \n \n-\n \n \n \n-\n \n \n \n(579,319\n)\n\n\nNet cash provided by operating activities\n \n6,202,919\n \n \n \n1,076,217\n \n \n \n15,944,841\n \n \n \n3,106,602\n \n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nCASH FLOWS FROM INVESTING ACTIVITIES\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nCash paid for capitalized software costs\n \n(3,043,634\n)\n \n \n(2,373,443\n)\n \n \n(7,546,346\n)\n \n \n(6,273,295\n)\n\n\nPurchase of equipment\n \n(447,802\n)\n \n \n(30,263\n)\n \n \n(1,265,447\n)\n \n \n(94,482\n)\n\n\nPurchase of intangible assets\n \n(1,862\n)\n \n \n-\n \n \n \n(3,798\n)\n \n \n(148,868\n)\n\n\nNet cash used in investing activities\n \n(3,493,298\n)\n \n \n(2,403,706\n)\n \n \n(8,815,591\n)\n \n \n(6,516,645\n)\n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nCASH FLOWS FROM FINANCING ACTIVITIES\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nProceeds from long-term debt, net\n \n                               -  \n \n \n \n                  4,993,885\n \n \n \n                               -  \n \n \n \n                19,466,887\n \n\n\nProceeds from notes payable\n \n                               -  \n \n \n \n                     347,691\n \n \n \n                               -  \n \n \n \n                  2,347,691\n \n\n\nSale of common stock under ATM, net\n \n                               -  \n \n \n \n                     899,567\n \n \n \n                               -  \n \n \n \n                     899,567\n \n\n\nRepayment of notes payable, net of prepayment penalty\n \n(13,020\n)\n \n \n(657,002\n)\n \n \n(327,597\n)\n \n \n(5,043,916)\n \n\n\nCash proceeds from exercise of options\n \n-\n \n \n \n-\n \n \n \n107,813\n \n \n \n-\n \n\n\nPreferred stock dividends\n \n(776,563\n)\n \n \n(776,563\n)\n \n \n(2,329,688\n)\n \n \n(2,329,688\n)\n\n\nContingent consideration payment for ResumeBuild\n \n-\n \n \n \n(62,500\n)\n \n \n(31,250\n)\n \n \n(187,500\n)\n\n\nNet payments for membership interest of WorkSimpli\n \n-\n \n \n \n-\n \n \n \n-\n \n \n \n(305,625\n)\n\n\nDistributions to non-controlling interest\n \n(36,000\n)\n \n \n(36,000\n)\n \n \n(108,000\n)\n \n \n(108,000\n)\n\n\nNet cash (used in) provided by financing activities\n \n(825,583\n)\n \n \n4,709,078\n \n \n \n(2,688,722\n)\n \n \n14,739,416\n \n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nNet increase in cash\n \n1,884,038\n \n \n \n3,381,589\n \n \n \n4,440,528\n \n \n \n11,329,373\n \n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nCash at beginning of period\n \n35,703,215\n \n \n \n11,906,741\n \n \n \n33,146,725\n \n \n \n3,958,957\n \n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nCash at end of period\n$\n37,587,253\n \n \n$\n15,288,330\n \n \n$\n37,587,253\n \n \n$\n15,288,330\n \n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nCash paid for interest\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nCash paid during the period for interest\n$\n630,342\n \n \n$\n717,054\n \n \n$\n1,913,049\n \n \n$\n1,485,242\n \n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nNon-cash investing and financing activities:\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nCashless exercise of options\n$\n-\n \n \n$\n579\n \n \n$\n5,127\n \n \n$\n744\n \n\n\nCashless exercise of warrants\n$\n-\n \n \n$\n-\n \n \n$\n16,305\n \n \n$\n-\n \n\n\nStock issued for noncontingent consideration payments\n$\n-\n \n \n$\n642,000\n \n \n$\n642,000\n \n \n$\n1,926,000\n \n\n\nSeries B Preferred Stock conversion\n$\n-\n \n \n$\n5,072,814\n \n \n$\n-\n \n \n \n5,072,814\n \n\n\nWarrants issued for debt instruments\n$\n-\n \n \n$\n(215,243\n)\n \n$\n-\n \n \n$\n873,100\n \n\n\nRight of use asset\n$\n4,353,166\n \n \n$\n62,053\n \n \n$\n6,684,397\n \n \n$\n155,168\n \n\n\nRight of use lease liability\n$\n4,353,166\n \n \n$\n62,053\n \n \n$\n6,684,397\n \n \n$\n155,168\n \n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n\nAbout the Use of Non-GAAP Financial Measures:To supplement our financial information presented in accordance with GAAP, we use adjusted EBITDA and adjusted EPS as non-GAAP financial measures to clarify and enhance an understanding of past performance. Additionally, we report telehealth adjusted EBITDA as a non-GAAP financial measure to clarify the financial performance of our core telehealth business excluding WorkSimpli. We believe that the presentation of these financial measures enhances an investor’s understanding of our financial performance. We further believe that these financial measures are useful financial metrics to assess our operating performance from period-to-period by excluding certain items that we believe are not representative of our core business. We use certain financial measures for business planning purposes and in measuring our performance relative to that of our competitors.\nAdjusted EBITDA is defined as income (loss) attributable to common shareholders before interest, taxes, depreciation, amortization, accretion, financing transaction expense, non-controlling interests, foreign currency translation, inventory and reserve adjustments on discontinued products, extraordinary litigation costs, loss on debt extinguishment, dividends, insurance acceptance and Sarbanes-Oxley readiness, acquisition costs, severance expenses and stock-based compensation expense. We have provided below a reconciliation of adjusted EBITDA to net loss attributable to common shareholders, its most directly comparable GAAP financial measure.\nAdjusted EPS is defined as the diluted net loss attributable to LifeMD, Inc common shareholders before interest, taxes, depreciation, amortization, accretion, financing transaction expense, non-controlling interests, foreign currency translation, inventory and reserve adjustments on discontinued products, extraordinary litigation costs, loss on debt extinguishment, dividends, insurance acceptance and Sarbanes-Oxley readiness, acquisition costs, severance expenses and stock-based compensation expense. We have provided below a reconciliation of adjusted EPS to Diluted loss per share attributable to LifeMD, Inc common shareholders, its most directly comparable GAAP financial measure.\nTelehealth adjusted EBITDA is defined as adjusted EBITDA for the telehealth business excluding WorkSimpli. We have provided below a reconciliation of telehealth adjusted EBITDA to net loss attributable to common shareholders solely related to the Company’s core telehealth business excluding WorkSimpli, LifeMD’s majority owned subsidiary. WorkSimpli does not have any overlap of revenues nor expenses with LifeMD’s telehealth business.\nWe believe the above financial measures are commonly used by investors to evaluate our performance and that of our competitors. However, our use of the terms adjusted EBITDA and adjusted EPS may vary from that of others in our industry. Telehealth adjusted EBITDA is specifically relevant to LifeMD to provide shareholders a comparable measure of profitability for our core telehealth business without the impact of our majority owned, but separately managed non-core subsidiary, WorkSimpli. Adjusted EBITDA, telehealth adjusted EBITDA and adjusted EPS should not be considered as an alternative to net loss before taxes, net loss per share, operating loss or any other performance measures derived in accordance with GAAP as measures of performance.\n\n\n\nReconciliation of Consolidated GAAP Net Loss to Consolidated Adjusted EBITDA\n \n \n \n \n \n \n \n \n \n \n \n\n\n(in whole numbers, unaudited)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n \nThree Months Ended September 30,\n \nNine Months Ended September 30,\n\n\n \n2024\n \n2023\n \n2024\n \n2023\n\n\nNet loss attributable to common shareholders\n$\n        (5,908,028\n)\n \n$\n           (6,898,998\n)\n \n$\n        (21,105,148\n)\n \n$\n        (19,193,579\n)\n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nInterest expense (excluding amortization of debt discount)\n \n458,154\n \n \n \n594,229\n \n \n \n1,266,412\n \n \n \n1,233,415\n \n\n\nDepreciation, amortization and accretion expense\n \n2,556,917\n \n \n \n1,769,134\n \n \n \n6,958,071\n \n \n \n4,807,979\n \n\n\nAmortization of debt discount\n \n100,443\n \n \n \n79,653\n \n \n \n301,331\n \n \n \n233,495\n \n\n\nLoss on debt extinguishment\n \n-\n \n \n \n-\n \n \n \n-\n \n \n \n325,198\n \n\n\nFinancing transactions expense\n \n-\n \n \n \n305,424\n \n \n \n323,372\n \n \n \n735,501\n \n\n\nLitigation costs (a)\n \n644,170\n \n \n \n420,404\n \n \n \n1,322,501\n \n \n \n1,426,330\n \n\n\nInventory and reserve adjustments on discontinued products\n \n85,000\n \n \n \n-\n \n \n \n651,142\n \n \n \n232,630\n \n\n\nSeverance costs\n \n621,391\n \n \n \n7,692\n \n \n \n1,142,068\n \n \n \n7,692\n \n\n\nAcquisitions expenses\n \n-\n \n \n \n86,942\n \n \n \n-\n \n \n \n127,138\n \n\n\nInsurance acceptance readiness\n \n391,803\n \n \n \n8,094\n \n \n \n1,361,637\n \n \n \n66,634\n \n\n\nSarbanes Oxley readiness\n \n203,342\n \n \n \n48,576\n \n \n \n386,470\n \n \n \n48,576\n \n\n\nAccrued interest on Series B Convertible Preferred Stock\n \n-\n \n \n \n39,884\n \n \n \n-\n \n \n \n506,991\n \n\n\nForeign exchange loss\n \n429,695\n \n \n \n272,899\n \n \n \n908,416\n \n \n \n796,619\n \n\n\nTaxes\n \n1,258,553\n \n \n \n70,378\n \n \n \n1,261,553\n \n \n \n70,378\n \n\n\nDividends\n \n799,929\n \n \n \n1,813,130\n \n \n \n2,920,102\n \n \n \n3,971,890\n \n\n\nStock-based compensation expense\n \n2,394,235\n \n \n \n3,318,253\n \n \n \n9,129,841\n \n \n \n8,843,736\n \n\n\nNet loss attributable to noncontrolling interests\n \n(345,767\n)\n \n \n839,288\n \n \n \n(187,729\n)\n \n \n2,247,055\n \n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nAdjusted EBITDA\n$\n          3,689,838\n \n \n$\n             2,774,982\n \n \n$\n             6,640,039\n \n \n$\n             6,487,678\n \n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n(a) For the three and nine months ended September 30, 2024, the Company included litigation costs related to a class action complaint alleging, inter alia, unauthorized disclosure of certain information of class members to third parties (the Marden v. LifeMD, Inc. case), as disclosed in the Company’s Form 10-Q for the third quarter ended September 30, 2024 and a heavily negotiated executive separation agreement. For the three and nine months ended September 30, 2023, the Company included litigation costs related to a purported breach of an investment bank engagement concerning potential debt financing (the William Blair LLC v. LifeMD, Inc. case) and a purported breach of a consulting services agreement for strategic and corporate development services (the Harborside Advisors LLC v. LifeMD, Inc. case), as disclosed in the Company’s Form 10-K for the fiscal year ended December 31, 2023 and filed on March 11, 2024.\n\n\n \n\n\n\n\n\n\nReconciliation of GAAP Diluted Loss per Share Attributable to Common Shareholders to Adjusted EPS\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n(unaudited)\nThree Months Ended September 30,\n \nNine Months Ended September 30,\n\n\n \n2024\n \n2023\n \n2024\n \n2023\n\n\nDiluted loss per share attributable to LifeMD, Inc. common shareholders\n$\n(0.14\n)\n \n$\n(0.20\n)\n \n$\n(0.52\n)\n \n$\n(0.58\n)\n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nAdjustments to Reconcile GAAP Diluted Loss Per Share to Adjusted EPS\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nInterest expense (excluding amortization of debt discount)\n \n0.01\n \n \n \n0.02\n \n \n \n0.03\n \n \n \n0.04\n \n\n\nDepreciation, amortization and accretion expense\n \n0.06\n \n \n \n0.05\n \n \n \n0.17\n \n \n \n0.15\n \n\n\nAmortization of debt discount\n \n-\n \n \n \n-\n \n \n \n0.01\n \n \n \n0.01\n \n\n\nLoss on debt extinguishment\n \n-\n \n \n \n-\n \n \n \n-\n \n \n \n0.01\n \n\n\nFinancing transactions expense\n \n-\n \n \n \n0.01\n \n \n \n0.01\n \n \n \n0.02\n \n\n\nLitigation costs\n \n0.02\n \n \n \n0.01\n \n \n \n0.03\n \n \n \n0.04\n \n\n\nInventory and reserve adjustments on discontinued products\n \n-\n \n \n \n-\n \n \n \n0.02\n \n \n \n0.01\n \n\n\nSeverance costs\n \n0.01\n \n \n \n-\n \n \n \n0.03\n \n \n \n-\n \n\n\nAcquisitions expenses\n \n-\n \n \n \n-\n \n \n \n-\n \n \n \n-\n \n\n\nInsurance acceptance readiness\n \n0.01\n \n \n \n-\n \n \n \n0.03\n \n \n \n-\n \n\n\nSarbanes Oxley readiness\n \n-\n \n \n \n-\n \n \n \n0.01\n \n \n \n-\n \n\n\nAccrued interest on Series B Convertible Preferred Stock\n \n-\n \n \n \n-\n \n \n \n-\n \n \n \n0.02\n \n\n\nForeign exchange (gain) loss\n \n0.01\n \n \n \n0.01\n \n \n \n0.02\n \n \n \n0.02\n \n\n\nTaxes\n \n0.03\n \n \n \n-\n \n \n \n0.03\n \n \n \n-\n \n\n\nDividends\n \n0.02\n \n \n \n0.05\n \n \n \n0.07\n \n \n \n0.12\n \n\n\nStock-based compensation expense\n \n0.06\n \n \n \n0.10\n \n \n \n0.22\n \n \n \n0.27\n \n\n\nNet loss attributable to noncontrolling interests\n \n-\n \n \n \n0.03\n \n \n \n-\n \n \n \n0.07\n \n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nAdjusted EPS\n$\n0.09\n \n \n$\n0.08\n \n \n$\n0.16\n \n \n$\n0.20\n \n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n\n\n\n\nReconciliation of Telehealth GAAP Net Loss to Telehealth Adjusted EBITDA\n \n \n \n \n \n \n \n \n \n \n \n \n\n\n(in whole numbers, unaudited)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n \nThree Months Ended September 30,\n \nNine Months Ended September 30,\n\n\n \n2024\n \n2023\n \n2024\n \n2023\n\n\nNet loss attributable to common shareholders\n$\n(4,612,049\n)\n \n$\n(10,044,756\n)\n \n$\n(20,401,514\n)\n \n$\n(27,731,584\n)\n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nInterest expense (excluding amortization of debt discount)\n \n456,151\n \n \n \n593,013\n \n \n \n1,263,120\n \n \n \n1,229,576\n \n\n\nDepreciation, amortization and accretion expense\n \n1,707,151\n \n \n \n1,150,718\n \n \n \n4,555,921\n \n \n \n3,176,361\n \n\n\nAmortization of debt discount\n \n100,443\n \n \n \n79,653\n \n \n \n301,331\n \n \n \n233,495\n \n\n\nLoss on debt extinguishment\n \n-\n \n \n \n-\n \n \n \n-\n \n \n \n325,198\n \n\n\nFinancing transactions expense\n \n-\n \n \n \n305,424\n \n \n \n323,372\n \n \n \n735,501\n \n\n\nLitigation costs (a)\n \n644,170\n \n \n \n420,404\n \n \n \n1,322,501\n \n \n \n1,426,330\n \n\n\nInventory and reserve adjustments on discontinued products\n \n85,000\n \n \n \n-\n \n \n \n651,142\n \n \n \n232,630\n \n\n\nSeverance costs\n \n621,391\n \n \n \n7,692\n \n \n \n1,142,068\n \n \n \n7,692\n \n\n\nAcquisitions expenses\n \n-\n \n \n \n86,942\n \n \n \n-\n \n \n \n127,138\n \n\n\nInsurance acceptance readiness\n \n391,803\n \n \n \n8,094\n \n \n \n1,361,637\n \n \n \n66,634\n \n\n\nSarbanes Oxley readiness\n \n203,342\n \n \n \n48,576\n \n \n \n386,470\n \n \n \n48,576\n \n\n\nAccrued interest on Series B Convertible Preferred Stock\n \n-\n \n \n \n39,884\n \n \n \n-\n \n \n \n506,991\n \n\n\nForeign exchange (gain) loss\n \n-\n \n \n \n-\n \n \n \n-\n \n \n \n-\n \n\n\nTaxes\n \n-\n \n \n \n-\n \n \n \n-\n \n \n \n-\n \n\n\nDividends\n \n812,562\n \n \n \n812,563\n \n \n \n2,437,687\n \n \n \n2,437,688\n \n\n\nStock-based compensation expense\n \n2,394,235\n \n \n \n3,318,253\n \n \n \n9,129,841\n \n \n \n8,843,736\n \n\n\nNet loss attributable to noncontrolling interests\n \n(345,767\n)\n \n \n839,288\n \n \n \n(187,729\n)\n \n \n2,247,055\n \n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nTelehealth Adjusted EBITDA\n$\n2,458,433\n \n \n$\n(2,334,252\n)\n \n$\n2,285,847\n \n \n$\n(6,086,983\n)\n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n(a) For the three and nine months ended September 30, 2024, the Company included litigation costs related to a class action complaint alleging, inter alia, unauthorized disclosure of certain information of class members to third parties (the Marden v. LifeMD, Inc. case), as disclosed in the Company’s Form 10-Q for the third quarter ended September 30, 2024 and a heavily negotiated executive separation agreement. For the three and nine months ended September 30, 2023, the Company included litigation costs related to a purported breach of an investment bank engagement concerning potential debt financing (the William Blair LLC v. LifeMD, Inc. case) and a purported breach of a consulting services agreement for strategic and corporate development services (the Harborside Advisors LLC v. LifeMD, Inc. case), as disclosed in the Company’s Form 10-K for the fiscal year ended December 31, 2023 and filed on March 11, 2024.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481160767"}